THELMA

TRASTUZUMAB EMTANSINE (TDM1) WITH NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2+ METASTATIC BREAST CANCER

CLINICAL TRIAL DETAILS

PHASE I MULTICENTER CLINICAL TRIAL EVALUATING THE COMBINATION OF TRASTUZUMAB EMTANSINE (T-DM1) AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN HER2-POSITIVE METASTATIC BREAST CANCER. THE PRIMARY GOAL IS TO DETERMINE THE MAXIMUM TOLERATED DOSE (MTD) OF THE COMBINATION OF T-DM1 AND NON-PEGYLATED LIPOSOMAL DOXORUBICIN IN METASTATIC BREAST CANCER (MBC) PATIENTS PREVIOUSLY TREATED WITH TAXANES AND TRASTUZUMAB-BASED THERAPY. IN ADDITION, PHARMACOKINETIC DATA ON THE COMBINATION OF T-DM1 AND LYPOSOMAL DOXORUBICIN WILL BE OBTAINED.

THELMA AT CLINICALTRIALS.GOV

COUNTRY

STATUS

TUMOR TYPE

PHASE

SITES

BREAST

Spain, France, Slovenia

Closing

PRESS RELEASE

SCIENTIFIC IMPACT

SABCS 2016 poster

ESMO 2019 poster

Cancers 2020

BLOG ARTICLES RELATED

TRIAL SITES

Hospital Universitari Vall D'Hebron (Spain) Hospital Universitario Ramón y Cajal (Spain) Hospital Clínic i Provincial de Barcelona (Spain) Institut Curie (France) | Hôpital Tenon AP-HP (France) Univerzitetni klinicni center Maribor Oddelek za onkologijo (Slovenia) Onkološki Inštitut Ljubljana (Slovenia)